Efficacy and Safety of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients: Pooled Data From Three 12-Month Multicenter, Open-Label, Prospective Studies

Transplantation Proceedings

Volumn 39, Issue 5, 2007, Pages 1386-1391

  Legendre, C ^a   Cohen, D ^a   Zeier, M ^a   Rostaing, L ^a   Budde, K ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; MYCOPHENOLIC ACID; STEROID;

ADULT; AGED; ARTICLE; BIOPSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL DISEASE; GRAFT FAILURE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; MULTICENTER STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; CADAVER; CONTINENTAL POPULATION GROUPS; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MIDDLE AGED; MYCOPHENOLIC ACID; PATIENT SELECTION; SAFETY; TABLETS, ENTERIC-COATED; TISSUE DONORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 34250192128     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.03.064     Document Type: Article

References (24)

1. Andrews P.A. Renal transplantation. BMJ 324 (2002) 530
2. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 345 (1995) 1321
3. Sollinger H.W., and U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60 (1995) 225
4. Ojo A.O., Meier-Kriesche H.U., Hanson J.A., et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69 (2000) 2405
5. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 24 (2001) 645
6. Knoll G., MacDonald I., Khan A., et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 14 (2003) 2381
7. Pelletier R.P., Akin B., Henry M.L., et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 17 (2003) 200
8. van Gelder T., Hilbrands L.B., Vanrenterghem Y., et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68 (1999) 261
9. Hardinger K.L., Brennan D.C., Lowell J., et al. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transplant Int 17 (2001) 609
10. Tierce J.C., Portefield Baxa J., Petrilla A.A., et al. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clinical Transplant 19 (2005) 779
11. Schnitzler M.A., Hardinger K.L., Burroughs T.E., et al. Consequences of immunosuppression minimization following diagnosis of gastrointestinal complications in renal transplant. Am J Transplant 5 Suppl 11 (2005) 242
12. Salvadori M., Holzer H., de Mattos A., et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4 (2004) 231
13. Salvadori M., and ERL B301 Study Group. Long-term administration of enteric-coated mycophenolate sodium in kidney transplant patients. Transplant Proc 37 (2005) 909
14. Budde K., Curtis J., Knoll G., et al., ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safety administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 4 (2004) 237
15. Budde K., Knoll G., Curtis J., et al. Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study. Transplant Proc 37 (2005) 912
16. Nashan B., Ivens K., Suwelack B., et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the myfortic prospective multicenter study. Transplant Proc 36 (2004) 521S
17. Kamar N., Garrigue V., Karras A., et al. Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: a randomized, multicenter study. Am J Transplant 6 (2006) 1042
18. Cibrik D.M., Jensik S., Meier-Krieche H.-U., et al. Enteric-coated mycophenolate sodium in combination with optimized Neoral dosing, basiliximab, and steroids results in good efficacy and renal function in renal transplant recipients in the first 6 months. Am J Transplant 4 Suppl 8 (2004) 218
19. Budde K., Bosmans J.-L., Sennesael J., et al. Reduced cyclosporin exposure is safe and efficacious in combination with basiliximab, enteric-coated mycophenolate sodium, and steroids. Am J Transplant 5 Suppl 11 (2005) 461
20. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31
21. Racusen L.C., Solez K., Colvin R.B., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 55 (1999) 7
22. Vitko S., Vogt B., Antoniadis A., et al., myPROMS study group. Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: results of a 12-month multicentre, open-label, prospective study. Am J Transplant 5 Suppl 11 (2005) 191
23. 2 monitoring of cyclosporine microemulsion. Transplantation 76 (2003) 903
24. Schnitzler M.A., Hardinger K.L., Burroughs T.E., et al. Consequences of immunosuppression minimization following diagnosis of gastrointestinal complications in renal transplant. Am J Transplant 5 Suppl 11 (2005) 242